பத்திரிகை அறிக்கை
டீல்
டீல் மதிப்பு—
டீல் vs வணிகம்39% capacity increase (expanding network from 719 beds to over 1,000 beds)
செயல்படுத்தும் காலம்2.5 ஆண்டு
அடிப்படை தரம்B
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)18.0% / 45.0%
EPS உயர்வு85.0%
அப்சைடு பேஸ் / புல் / பேர்55.0% / 105.0% / -25.0%
கால எல்லை24-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம்(04 ஆக. 2026)₹170.0
சமீபத்திய முடிவு விலை(12 நவ. 2026)₹145.05
தொடங்கியதிலிருந்து வருமானம்-14.7%
α vs Smallcap 250-14.0%
α vs சொந்தத் துறை-9.1% (ஹெல்த்கேர் இடைநிலை -4.9%, 55 முதிர்ந்த தேர்வுகளின் அடிப்படையில்)
நேர்மறைகள்
- Q1 FY27 PAT surged 65.7% YoY to ₹12.7 Cr, driven by 300 bps EBITDA margin expansion to 20.4%.
- Capacity expanding 39% from 719 beds to over 1,000 beds across Jamshedpur (Q4 FY27) and a 7th greenfield/brownfield facility.
- Raipur hospital progressing toward Q3 FY27 breakeven and adding high-margin specialties like liver transplant.
- Solid balance sheet with low leverage (D/E 0.34) and high return ratios (ROCE 20.0%).
அபாயங்கள்
- Dilution of near-term margins and low total occupancy (45.5%) during new hospital gestation periods.
- High regional concentration in West Bengal, Eastern India, and neighboring regional clusters.
- Intense competition from large national chains (Apollo, Fortis, Max, KIMS) expanding into Tier-2 Eastern Indian cities.
முழு AI சுருக்கம்
1. Ramp-Aware Impact Math & Earnings Trajectory
- Q1 FY27 Baseline: Total income grew 18% YoY to ₹128.2 Cr (quarterly run-rate ~₹512 Cr annualized). PAT expanded 65.7% YoY to ₹12.7 Cr, implying an annualized PAT run-rate of ~₹50.8 Cr.
- Capacity Ramp: Installed beds are expanding from 719 to >1,000 beds (~39% increase). Current occupancy is suppressed at 45.5% overall due to the newly commissioned Raipur facility, while mature hospitals enjoy 58% occupancy.
- Steady-State Math: Once Raipur breaks even (projected Q3 FY27) and Jamshedpur ramps up in FY28, steady-state revenues are expected to rise to ~₹680-720 Cr. Operating leverage will expand EBITDA margins from 20.4% toward 22-23%, producing steady-state PAT of ~₹75-85 Cr.
- EPS & Valuation Impact: Annualized Q1 FY27 EPS is ~₹6.25. On current price of ₹168, the stock trades at ~26.8x FY27 annualized EPS (compared to historical TTM trailing P/E of 80x which reflects earlier FY26 margin compression).
2. தொழில்துறைச் சூழல் & மூலதனத் தீவிரம்
- Industry Capital Intensity: HIGH. Building and equipping secondary/tertiary care hospitals requires long-term capital and 12-24 months of operational gestation per hospital.
- Industry Structure: Regional healthcare demand in Eastern India is growing at ~12-14% CAGR due to low bed density per thousand population and increasing health insurance penetration.
3. Fundamental & Quality Profile
- ROCE: 20.0%, indicating disciplined capital allocation even through expansion cycles.
- Leverage: Debt stands at ₹91 Cr against Net Worth of ₹269 Cr (D/E 0.34), leaving ample room for ongoing capex without equity dilution.
- Promoter Holding: Stable at 65.57%.
4. மதிப்பீடு & சூழ்நிலைப் பகுப்பாய்வு
- Base Case (55% Upside / Target ₹260): Steady-state PAT reaches ~₹75 Cr by FY28 as Raipur and Jamshedpur mature. Applying a reasonable hospital multiple of 28x forward P/E yields a market cap of ~₹2,100 Cr.
- Bull Case (105% Upside / Target ₹345): Rapid occupancy expansion to 62%+ across all units, driving PAT to ₹95 Cr with multiple re-rating to 32x.
- Bear Case (-25% Downside / Target ₹126): Delays in Jamshedpur commissioning and sustained EBITDA losses at Raipur pull down PAT to ₹35 Cr, with P/E de-rating to 25x.
5. தீர்ப்பின் காரணம்
GPT Healthcare exhibits strong operational turnaround in Q1 FY27 with clear growth visibility from 719 to 1,000+ beds. While high capital intensity and ramp-up risks prevent a 'STRONG_CANDIDATE' classification, it stands out as a high-quality 'POSSIBLE' multibagger candidate over a 24-36 month horizon.
2026-08-03 நிலவரப்படி பகுப்பாய்வு (விலை ₹168.00) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
